Search

Your search keyword '"Sisk, Anthony"' showing total 4 results
Start Over Author "Sisk, Anthony" Journal european urology
4 results on '"Sisk, Anthony"'

1. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

Author

Salami, Simpa, Tosoian, Jeffrey, Nallandhighal, Srinivas, Jones, Tonye, Brockman, Scott, Elkhoury, Fuad, Bazzi, Selena, Plouffe, Komal, Siddiqui, Javed, Liu, Chia-Jen, Kunju, Lakshmi, Morgan, Todd, Natarajan, Shyam, Boonstra, Philip, Sumida, Lauren, Tomlins, Scott, Udager, Aaron, Sisk, Anthony, Marks, Leonard, and Palapattu, Ganesh

Subjects
Cancer progression, Gene fusions, Immunohistochemistry, Low-grade cancer, Next-generation sequencing, Prostate cancer, Tumor clonality, Cohort Studies, Humans, Image-Guided Biopsy, Longitudinal Studies, Male, Middle Aged, Neoplasm Grading, Prostate, Prostatic Neoplasms
Abstract

BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p

Published
2021

2. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer

Author

Houlahan, Kathleen E, Salmasi, Amirali, Sadun, Taylor Y, Pooli, Aydin, Felker, Ely R, Livingstone, Julie, Huang, Vincent, Raman, Steven S, Ahuja, Preeti, Sisk, Anthony E, Boutros, Paul C, and Reiter, Robert E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Urologic Diseases, Cancer, Biomedical Imaging, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Aged, Gene Dosage, Gene Expression Profiling, Genome, Humans, Male, Middle Aged, Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms, RNA, Long Noncoding, RNA, Messenger, RNA, Small Nuclear, Transcriptome, Tumor Burden, Tumor Microenvironment, Prostate cancer, Multiparametric magnetic resonance imaging visibility, Radiogenomics, Nimbosus, Transcriptomics, Urology & Nephrology, Clinical sciences
Abstract

Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results